Nimotuzumab in Adults With Glioblastoma Multiforma
Phase-III Study of Standard Radiotherapy Plus Concomitant and Adjuvant OSAG 101 (Theraloc®) Plus Temozolomide vs. Standard Radiotherapy Plus Concomitant and Adjuvant Temozolomide in Patient With Newly Diagnosed, Histologically Confirmed Glioblastoma Multiforme Grade IV
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Hamburg, Germany, 20246
- Dep. Neurosurgery, Univ. Hamburg
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient signed informed consent
- Newly diagnosed, histologically confirmed glioblastoma multiforme grade IV
- Condition is measurable by MRI in at least one dimension
- Age 18-70
- Karnofsky-Index > 40
- Treatment in a study center
- Female patients with a childbearing potential must have a negative pregnancy test within one week before inclusion in the trial. Those female and male patients admitted in the study must use a reliable method of contraception.
Adequate haematological, renal and hepatic function:
- Leucocytes >2.0x10^9/l
- Hb> 10g/dl
- Billirubin total < 2.5x upper limit of normal (ULN)
- Creatinin i.S. < 1.5x ULN
- AST (GOT)/ALT (GPT) < 5x ULN
Exclusion Criteria:
- Patients with history of anaphylactic reaction to murine or humanized antibody
- Patients with evidence second malignancy
- Patients who are pregnant or patients who refused adequate contraceptive precaution (female and male) during the trial
- Pregnancy and lactation
- Other conditions considered by investigators as sound reasons for disqualification from enrolment into the study such as: potential non compliance with protocol requirement
- No MRI for tumour evaluation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
PLACEBO_COMPARATOR: Arm B
adults with TMZ, RT
|
monoclonal antibody
|
|
EXPERIMENTAL: Arm A
adults with TMZ, RT, nimotuzumab
|
monoclonal antibody
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Progression-free interval determined by MRI
Time Frame: week 12, 24, 36, 52
|
week 12, 24, 36, 52
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Overall survival Time to reintervention Response rate according to RECIST criteria Toxicity according to CTC criteria Symptom control Quality of life
Time Frame: week 12, 24, 36, 52
|
week 12, 24, 36, 52
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Manfred Westphal, Prof. MD, University Hamburg
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- OSAG101-BSA05
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.